A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT02653976 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral T-Cell Lymphoma

Interventions

DRUG: SP-02L (darinaparsin for injection)

Sponsor

Solasia Pharma K.K.